Secondary endpoints included safety profile, dose intensity (mg m−2 per week), relapse-free survival and overall survival.
In general, they are phase I/II studies - which, as noted above, investigate the safety profile, dose level and response to new drugs [ 15].
Based on data from the Attard study, including clinical responses, maximization of anticipated endocrinologic effects, and its favorable safety profile, dose escalation of abiraterone acetate was stopped at 1,000 mg/day.
The primary objectives were to determine the toxicity profile, dose-limiting toxicity (DLT), maximum-tolerated dose (MTD) and pharmacokinetic profile of SP1049C.
The development of apixaban reflects a strategy to optimize the clinical pharmacology profile, dosing posology, trial designs, and statistical analyses across multiple indications, and to seek alignment with global health authorities.
The main objectives of early‐phase clinical studies of cancer immunotherapy are to determine safety profile, optimal dose, dosing regimen, dosing schedule, and efficacy.
Prospective studies are needed, but results may provide early insight into optimizing crossbred cannabis strains, synergistic biochemical profiles, dosing, and patterns of use in the treatment of headache, migraine, and chronic pain syndromes.
However, these results may provide early insight and a framework for direction into optimizing crossbred cannabis strains, synergistic biochemical profiles, dosing, and patterns of use that may be of clinical benefit in the treatment of headache and migraine, as well as other chronic pain syndromes.
CAPIRI-Bev has a less favourable toxicity profile, requiring dose reductions, in order to be considered as an option in first-line treatment of patients with mCRC.
The apparent discrepant findings may be explained by differences in POP exposure profile and dose resulting from variation in lifestyle and diet or they may reflect random variation.
Weekly infusions of paclitaxel have gained wide popularity because of the favourable toxicity profile allowing dose intensifications (Seidman et al, 1997; Perez et al, 2001).
